A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Trial Profile

A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Diphencyprone (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 11 May 2017 According to a RXi Pharmaceuticals media release, the company expects early read-outs in the second half of 2017.
    • 13 Dec 2016 According to a RXi Pharmaceuticals media release, the read-out of the first cohort data will happen in the first half of 2017, the complete readout of the final study is anticipated in the second half of 2017.
    • 13 Dec 2016 According to a RXi Pharmaceuticals media release, an additional cohort will be added in January 2017 to evaluate an optimized treatment/dosing regimen with a reduced initial sensitizing dose applied to the inner arm and all warts which may result in a more streamlined treatment phase.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top